AbbVie Inc. (NYSE:ABBV) ranks among the top picks for a retirement portfolio. The FDA received a New Drug Application from ...

In a landmark discovery, scientists from the University of Cambridge and University College London have, for the first time, ...

Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a ...

For more than a decade, Carnegie Mellon neuroscientist Aryn Gittis has been unraveling the mystery of how the brain controls movement — research now pointing toward new treatments for Parkinson’s ...

The toxins could potentially be used as ‘markers’ for doctors to identify Parkinson’s patients at a higher risk of developing dementia ...

Empatica, a pioneer in digital biomarker development and patient monitoring using wearables and AI, announced the successful ...

Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced a significant milestone in its ongoing Phase 2 clinical study, ACTIVATE (clinicaltrials ...

The common myths about Parkinson’s disease and treatments - People have lots of misconceptions about Parkinson’s disease and how it develops, here are the ...

Our community is divided over mandatory online GP bookings, with some praising the convenience and reduced surgery visits, ...

A new study has identified a specific substance produced by a common gut bacterium that can travel to the brain and cause the ...

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch next year.

Now, scientists at La Jolla Institute for Immunology (LJI) and Columbia University Irving Medical Center have uncovered evidence that ALS may be an autoimmune disease. The researchers discovered that ...